Jeffrey Leiden
Executive ChairmanVertex Pharmaceuticals
PharmaceuticalsView Profile →Chairman of the Board of Management and Chief Executive Officer · Bayer
Bill Anderson is Bayer’s chief executive officer, following leadership of Roche Pharmaceuticals and Genentech and earlier engineering, finance and biotechnology roles.
Last reviewed: Nov 15, 2026
Bill Anderson is Bayer’s chief executive officer, following leadership of Roche Pharmaceuticals and Genentech and earlier engineering, finance and biotechnology roles.
Anderson began in chemical engineering before moving into biotechnology management. At Ethyl Corporation, his work included process research in the Netherlands in 1989 and engineering and shift supervision in Belgium the following year. He joined Raychem in 1995 in business development and marketing, moving from plant and process work toward commercial responsibilities.
Biogen recruited him in 1997 as a business planning manager. He subsequently ran its United Kingdom and Ireland business, became a vice president responsible for finance and business planning, and in 2004 took charge of the neurology business unit. The sequence included both financial management and responsibility for a therapeutic business.
He joined Genentech in 2006 to lead its immunology and ophthalmology business, adding leadership of BioOncology in 2010. In 2013, he moved to Roche Pharmaceuticals as head of global product strategy and chief marketing officer. He returned to Genentech’s North American operations in 2016, preceding his appointment as its CEO effective January 1, 2017.
Anderson became CEO of Roche Pharmaceuticals in 2019. Bayer appointed him to its management board on April 1, 2023, with the chief executive role following on June 1.
At Bayer, his tenure includes the introduction of Dynamic Shared Ownership. The company describes this operating model as organizing work around cross-functional teams and customer outcomes, with shorter decision cycles and fewer management layers.